The Latest Breaking News from Indivior

Virginia-based Indivior, a developer of opioid addiction treatments, continues to hold down a place in Barchart’s Top 100 Stocks to Buy. Up 192% in 2025, its P/E is declining despite the stock’s gains over the past year. Here’s why.

In Monday’s trading, the opioid-treatment pharmaceutical company’s stock moved into the top 50 in Barchart’s Top 100 Stocks to Buy in 46th position, up 11 spots from Friday. With profits rising, it’s got momentum on its side.

Paddy Power owner will make switch to its ‘natural home’ by May in further blow to London Stock Exchange

Move is latest in number of delistings and IPO snubs to London Stock Exchange, including Tui

Rolling, live coverage of business, economics and financial markets as British bond yields rise amid expectations of stubbornly high interest rates

The company that makes the opioid addiction treatment drug Suboxone has reached a $102.5 million settlement of antitrust claims with 41 states and the District of Columbia

Opvee is similar to naloxone, the life-saving drug that has been used for decades to quickly counter overdoses of heroin, fentanyl and prescription painkillers.

U.S. health regulators have approved a new nasal spray to reverse overdoses due to fentanyl and other powerful opioids

Last week, Addex Therapeutics Ltd (NASDAQ:ADXN) terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow rate of patient recruitment.  Addex is suspending its financial guidance. Hence HC Wainwright downgraded its rating to Neutral from Buy without a price target, as dipraglurant…